Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP recommends Perricone modify ads

This article was originally published in The Tan Sheet

Executive Summary

Perricone MD will clarify Cold Plasma Skin Cream claims that are based on consumer perceptions rather than "clinical proof," as recommended by the Electronic Retailing Self-Regulation Program. For example, a four-week, blinded consumer perception study in which 202 subjects evaluated the product after the first and fourth weeks, did not support claims that "skin will look lifted and firmer in minutes." Perricone based the claim on 85 percent of study participants saying Cold Plasma imparted "instant results." But ERSP said the product's capacity to firm and lift were not addressed in the survey question. The watchdog also said the firm could not assume that consumers understood the word "instant" to mean "within minutes." While Perricone disagrees with ERSP, it says it will take the panel's guidance into consideration

You may also be interested in...



Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

Topics

UsernamePublicRestriction

Register

PS103914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel